Skip to main content


Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology 4/2019

Ausgabe 4/2019

Inhaltsverzeichnis ( 25 Artikel )

11.06.2019 | Review Article | Ausgabe 4/2019

Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer

G. Roviello, F. U. Conter, E. Mini, D. Generali, M. Traversini, D. Lavacchi, S. Nobili, N. Sobhani

29.06.2019 | Review Article | Ausgabe 4/2019

Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer

Annie Roys, Xing Chang, Yang Liu, Xiaobo Xu, Yingliang Wu, Daiying Zuo

31.07.2019 | Review Article | Ausgabe 4/2019

Current status of nanomedicine in the chemotherapy of breast cancer

A. I. Fraguas-Sánchez, C. Martín-Sabroso, A. Fernández-Carballido, A. I. Torres-Suárez

08.07.2019 | Original Article | Ausgabe 4/2019

Population pharmacokinetics of trabectedin in adolescent patients with cancer

Italo Poggesi, Belén Valenzuela, Daniele Ouellet, Martha Gonzalez, Vera Hillewaert, Sylvain Baruchel, Elizabeth Fox, Juan Jose Perez-Ruixo

08.07.2019 | Original Article | Ausgabe 4/2019

Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway

Zhe Cha, Jianzhang Cheng, Hui Xiang, Jingjing Qin, Yujia He, Zhiping Peng, Jianhua Jia, Huarong Yu

18.07.2019 | Original Article | Ausgabe 4/2019

Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft

Shaun D. Fontaine, Byron Hann, Ralph Reid, Gary W. Ashley, Daniel. V. Santi

19.07.2019 | Original Article | Ausgabe 4/2019

A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells

Kathryn E. Burns, Daniel Allright, David Porter, Michael P. Findlay, Nuala A. Helsby

19.07.2019 | Original Article | Ausgabe 4/2019

Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects

Vassilios Aslanis, Kenichi Umehara, Felix Huth, Taoufik Ouatas, Savita Bharathy, Andrew Avigdor Butler, Wen Zhou, Brian Gadbaw

31.07.2019 | Original Article | Ausgabe 4/2019

A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer

Cody J. Peer, Keith T. Schmidt, Jessica D. Kindrick, Joel R. Eisner, Victoria V. Brown, Edwina Baskin-Bey, Ravi Madan, William D. Figg

31.07.2019 | Original Article | Ausgabe 4/2019

Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines

Dong-Joon Min, Yingdong Zhao, Anne Monks, Alida Palmisano, Curtis Hose, Beverly A. Teicher, James H. Doroshow, Richard M. Simon

31.07.2019 | Original Article | Ausgabe 4/2019

Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

Javier Munárriz, Gaspar Reynés, Luisa Sánchez-Lorenzo, Emilio Esteban, Laura Basterretxea, Leticia de Avila-Lizárraga, Miguel Angel Climent, María José Juan-Fita, Corina Escoín, Javier Puente, Javier Cassinello, Sergio Vázquez, Isabel Chirivella

02.08.2019 | Original Article | Ausgabe 4/2019

A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24

Mansoor Raza Mirza, Troels K. Bergmann, Morten Mau-Sørensen, René dePont Christensen, Elisabeth Åvall-Lundqvist, Michael J. Birrer, Morten Jørgensen, Henrik Roed, Susanne Malander, Flemming Nielsen, Ulrik Lassen, Kim Brøsen, Line Bjørge, Johanna Mäenpää

05.08.2019 | Original Article | Ausgabe 4/2019 Open Access

A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics

Jianke Li, Denise Trone, Jeanne Mendell, Patrick O’Donnell, Natalie Cook

05.08.2019 | Original Article | Ausgabe 4/2019

Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma

Mi Na Kim, Seung Min Lee, Jin Sung Kim, Seong Gyu Hwang

06.08.2019 | Original Article | Ausgabe 4/2019

A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study

Song Zheng, Yao Zhou, Yangcheng Sun, Zhen Wang, Yidan Lu

07.08.2019 | Original Article | Ausgabe 4/2019

Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors

Samuel J. Reddick, Olivia Campagne, Jie Huang, Arzu Onar-Thomas, Alberto Broniscer, Amar Gajjar, Clinton F. Stewart

19.08.2019 | Original Article | Ausgabe 4/2019 Open Access

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

F. J. Esteva, Y. V. Baranau, V. Baryash, A. Manikhas, V. Moiseyenko, G. Dzagnidze, E. Zhavrid, D. Boliukh, D. Stroyakovskiy, J. Pikiel, A. E. Eniu, R. K. Li, A. V. Rusyn, B. Tiangco, S. J. Lee, S. Young Lee, S. Y. Yu, J. Stebbing

19.08.2019 | Original Article | Ausgabe 4/2019 Open Access

Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma

Eisei Kondo, Takashi Ikeda, Hiroaki Goto, Momoko Nishikori, Naoko Maeda, Kimikazu Matsumoto, Hideo Kitagawa, Naoto Noda, Saori Sugimoto, Junichi Hara

19.08.2019 | Original Article | Ausgabe 4/2019 Open Access

FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer

Mingyou Xing, Jun Wang, Qin Yang, Yu Wang, Jiansha Li, Jing Xiong, Sheng Zhou

23.08.2019 | Original Article | Ausgabe 4/2019

Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer

Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Yu Miura, Kosuke Hashimoto, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu

23.08.2019 | Original Article | Ausgabe 4/2019 Open Access

Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study

Sacha I. Rothschild, Daniel Betticher, Reinhard Zenhäusern, Sandro Anchisi, Roger von Moos, Miklos Pless, Peter Moosmann, Razvan A. Popescu, Antonello Calderoni, Marco Dressler, Daniel Rauch, Stefanie Pederiva, Regina Woelky, Claudia Papet, Vera Bühler, Markus Borner

23.08.2019 | Original Article | Ausgabe 4/2019 Open Access

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Ken Ogasawara, Simon Zhou, Gopal Krishna, Maria Palmisano, Yan Li

28.08.2019 | Original Article | Ausgabe 4/2019

A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors

Janice M. Mehnert, Amanda D. Kaveney, Jyoti Malhotra, Kristen Spencer, Daniella Portal, Susan Goodin, Antoinette R. Tan, Joseph Aisner, Rebecca A. Moss, Hongxia Lin, Joseph R. Bertino, Darlene Gibbon, Laurence A. Doyle, Eileen P. White, Mark N. Stein

23.08.2019 | Clinical Trial Report | Ausgabe 4/2019 Open Access

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

Jeffrey Melson Clarke, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S. Yousuf Zafar, Michael Morse, Evan Dropkin, Leigh Howard, Margot O’Neill, Christel N. Rushing, Donna Niedzwiecki, Hollie Watson, Emily Bolch, Christy Arrowood, Yingmiao Liu, Andrew B. Nixon, Herbert I. Hurwitz

13.08.2019 | Short Communication | Ausgabe 4/2019

A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma

Olga Vornicova, Nissim Haim, Gil Bar-Sela

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.